Targeting a specific gene to improve treatment for pancreatic cancer
Official title: Targeting GCNT3 for Pancreatic Cancer
Funded at Oklahoma City VA Medical Center · NIH-10948921 · Data updated 2026-11-12
This study is looking at how a gene called GCNT3 affects pancreatic cancer and is testing a new treatment that might help existing chemotherapy work better, which could lead to improved outcomes for patients.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Oklahoma City VA Medical Center NIH-funded |
| Lab location | 1 site (Oklahoma City, United States) |
| Project start | October 1, 2021 |
| Project end | March 31, 2026 |
| Funding year | 2025 |
| NIH project number | 5I01BX005319-04 |
| Project ID | NIH-10948921 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with pancreatic cancer, particularly those who have not responded well to standard treatments.
✕Less likely to help
Patients with early-stage pancreatic cancer or those who have not been diagnosed with the disease may not benefit from this research.
What this research studies
This research investigates the role of the GCNT3 gene in pancreatic cancer, which is known for its high mortality rate and low survival rates. The study aims to understand how GCNT3 contributes to cancer growth and resistance to treatment. By using advanced molecular techniques, researchers are exploring a novel inhibitor, talniflumate, that may effectively target GCNT3 and enhance the effectiveness of existing chemotherapy drugs. Patients may benefit from new treatment strategies that improve drug responsiveness and potentially increase survival rates.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for pancreatic cancer, improving survival rates and quality of life for patients.
How similar studies have gone: While targeting specific genes in cancer treatment is a growing field, this particular approach focusing on GCNT3 is relatively novel and has not been extensively tested in previous studies.
Where this research is happening
-
Oklahoma City VA Medical Center
Oklahoma City, United States Active
Researchers
- Principal investigator: Rao, Chinthalapally V. — Oklahoma City VA Medical Center
- Study coordinator: Rao, Chinthalapally V.
Related research
Other NIH-funded projects on the same topics.
-
Microbial Dysbiosis and Its Role in Pancreatic Cancer
A doctor-researcher team at Northwestern University is studying how gut bacteria influence pancreatic cancer and its response to immunotherapy to find new ways to help patients.
-
Targeting aberrant enhancer landscapes in pancreatic cancer
A patient-facing look at a project that aims to understand how pancreatic cancer changes its cell identity and what that means for treatment.
-
Exosome-based microRNA biomarkers for early, non-invasive detection of pancreatic cancer
A study to develop a blood test that uses tiny RNA signals in exosomes to detect pancreatic cancer early, aiming to help people at risk or with early disease.
-
Exosome-based microRNA biomarkers for early detection of pancreatic cancer
A patient-friendly look at a study using tiny blood-based RNA markers inside exosomes to catch pancreatic cancer early without invasive procedures.
-
Programmable implanted living materials to fight pancreatic cancer
A patient-facing program will explore a safe, implantable living material that delivers sequential immunotherapies directly to pancreatic tumors to help fight cancer.
-
Targeting how platelets and pancreatic cancer talk to each other
A study exploring whether blocking the interaction between platelets and pancreatic cancer cells could slow cancer growth and spread and help identify new biomarkers.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.